Enjoy complimentary customisation on priority with our Enterprise License!
The RNAi drug delivery market size is estimated to grow by USD 109.73 billion at a CAGR of 20.83% between 2022 and 2027. The high target affinity and specificity of RNAi therapeutics make them attractive for treating a wide range of diseases, including neurological disorders. Increasing research activities in the pharmaceutical and biotechnology sectors are leading to the development of new RNAi therapeutics and expanding their applications. The increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's disease, is driving the demand for effective treatments, further fueling market growth in this area.
It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
This market report extensively covers market segmentation by technology (nanoparticle drug delivery, pulmonary drug delivery, nucleic acid drug delivery, and aptamer drug delivery), application (infectious diseases, oncology, cardiology, neurology, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The market share growth by the nanoparticle drug delivery segment will be significant during the forecast period. Nanoparticle drug delivery systems are modern technologies that are rapidly developing technology materials in the nanoscale range and are employed to serve as therapeutic agents to targeted sites in a controlled manner. Nanotechnology provides numerous advantages in the treatment of chronic human diseases by delivering precise medications to specified locations and targets.
Get a glance at the market contribution of various segments View the PDF Sample
The nanoparticle drug delivery segment showed a gradual increase in the market share of USD 12.45 billion in 2017. Characteristics of nanoparticles, such as distinctive size, are useful for the efficient delivery of RNAi therapeutics. As a result, nanoparticle drug delivery systems are used in the treatment of cancer, and it is an emerging therapeutic strategy for combating cancer. Thus, the application of nanoparticle drug delivery systems in cancer treatment coupled with the increasing cases of cancer will drive the growth of the segment and, in turn, the market in focus during the forecast period
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, there is a rise in the number of cancer and metabolic diseases due to excessive smoking and consumption of alcohol. The availability of improved diagnostic modalities has made it possible to identify several rare diseases, as a result of which many market vendors, along with researchers, are discovering and coming up with RNAi therapies.
Currently, RNAi drug delivery is having high demand in the US. The region has highly advanced research and manufacturing facilities, which is one of the reasons for the high growth rate of the market in North America. For example, in April 2020, Alnylam entered a development and commercialization collaboration with the Dicerna subsidiary of Novo Nordisk to advance investigational RNAi therapeutics for the treatment of alpha-1 liver disease. Such factors will drive the growth of the market during the forecast period.
The market is experiencing rapid growth, fueled by advancements in nanoparticle-based delivery systems and aptamer drug delivery technology. These innovations are enhancing the efficacy of molecular diagnostics and personalized medicine for various conditions, including autoimmune hepatitis, ocular disorders, and oncology. With the global population aging, there is a rising need for targeted therapies to address metabolic disorders and malignancies. The use of artificial intelligence in drug development is also gaining traction, as seen in the development of drugs like Atorvastatin Calcium. These trends underscore the significant potential of RNAi in revolutionizing pharmaceuticals for a range of diseases. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high target affinity and specificity of RNAi therapeutics are the key drivers for the growth of the market.
RNAi therapeutics demonstrate remarkable effectiveness against their specific targets. RNAi molecules bind to target genes with exceptional affinity, facilitated by complementary base pairing that involves hydrogen bond formation in nucleic acids. This high-affinity binding enables RNAi and antisense oligonucleotides to regulate gene expression through various mechanisms. Some key advantages of RNAi therapeutics include their ability to target virtually any gene in the genome, their high potency and long-lasting effects, and their ability to be administered through multiple routes, including intravenous, subcutaneous, and inhalation delivery. These benefits are complemented by advancements in these technologies such as Aptamer Drug Delivery Technology, Nanoparticle Drug Delivery Technology, and Nanoparticle-based delivery systems. In fields like Oncology, Ophthalmology, and for treating Ocular Disorders, these RNAi therapeutics hold promise for personalized medicine approaches. These factors are expected to lead to the introduction and approval of new RNAi drugs, driving market growth during the forecast period.
The increasing R&D for RNAi therapy by vendors is the primary trend in the market. Vendors operating in the market have increased their focus on R&D for RNAi therapy to expand their offerings. For instance, In June 2022, Alnylam initiated platform advancements that enabled the development of a new conjugate technology, C16. With a new conjugate, RNAi therapy can target new extrahepatic tissues, including the eye, the lung, and the central nervous system. Phase 1 ALN-APP program in early-onset Alzheimer's disease is the first clinical program to utilize C16.
Moreover, in November 2021, Novo Nordisk entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). Dicerna focuses on RNAi-based therapeutics. Moreover, the RNAi platform from Dicerna to Novo Nordisk's already existing research technology platforms strengthens the company's objective of utilizing a wide variety of technology platforms that apply to all its therapeutic emphasis areas. Such trends will positively impact the growth of the market in focus during the forecast period.
The high price of RNAi drugs is the major challenge in the market. RNAi-based drugs are very effective for the treatment of various chronic diseases, However, their high price makes them unaffordable for the patients. Manufacturers of RNAi-based drugs are investing huge sums in the R&D of these kinds of therapies. Factors such as a highly technically skilled workforce and complex manufacturing and scaling-up facilities are responsible for the high prices of these drugs.
Moreover, after 16 years of continuous research and USD 2.5 billion in investments, Alnylam offers ONPATTRO for the treatment of hATTR amyloidosis, which costs around USD 450,000 per patient. However, most counties across the world do not have reimbursement policies for such expensive therapies. Thus, the high cost of RNAi drugs will negatively impact the growth of the market in focus during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence in the market.
Arbutus Biopharma Corp.: The company offers RNAi drug delivery solutions such as AB 729 is an RNA interference therapeutic targeted to hepatocytes using Arbutus novel covalently conjugated N acetylgalactosamine delivery technology that enables subcutaneous delivery.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The market is witnessing significant growth, driven by advancements in nanoparticle drug delivery technology and nucleic acid drug delivery technology. Companies like AstraZeneca and Ionis Pharmaceuticals are actively involved in developing RNAi-based therapies for various conditions, including respiratory disorders and ophthalmology. These therapies target specific genetic abnormalities associated with diseases, offering personalized treatment options. Regulatory bodies like the United States Food and Drug Administration play a crucial role in approving these innovative treatments. The market is also supported by initiatives from organizations like the American Cancer Society and the International Agency for Research on Cancer to address cancer and viral infections like Hepatitis B and Hepatitis C.
The market is expanding rapidly, with a focus on innovative therapies like Leqvio and lipid-based carriers for miRNA delivery. Companies like Enzon Pharmaceuticals are advancing RNAi therapeutic drugs targeting tumor growth and other conditions prevalent in the geriatric population. The pharmaceutical industry is actively involved in developing RNA interference (RNAi) technologies, leveraging pulmonary drug delivery technology and RNA molecules to enhance drug efficacy. While GLOBOCAN 2020 report insights guide strategic planning, company profiling and careful consideration of restraints are essential for navigating this dynamic market.
Market Scope |
|
Report Coverage |
Details |
Page number |
175 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 20.83% |
Market growth 2023-2027 |
USD 109.73 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
19.28 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals Inc., Bayer AG, Benitec Biopharma Inc., BioNTech SE, Bristol Myers Squibb Co., CureVac AG, e therapeutics plc, F. Hoffmann La Roche Ltd., Novartis AG, Novo Nordisk AS, Phio Pharmaceuticals, Sanofi, Silence Therapeutics plc, Silenseed Inc., siRNAgen Therapeutics Corp., Sirnaomics Inc., Sylentis S.A., Thermo Fisher Scientific Inc., and TransCode Therapeutics Inc. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Technology
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.